Updates

Tweets by @cellcentric

All our updates and events through tweets

CellCentric’s first-in-class cancer drug CCS1477 inhibits twin proteins p300/CBP. This impacts the activation of certain genes important to cancer. pic.twitter.com/wSXeFKTpRv

#ASCO21 CellCentric’s CMO, Tomasz is there, virtually. CCS1477 first in class p300/CBP inhibitor to treat multiple cancer types. pic.twitter.com/9aPUN04WHn

Targeting p300/CBP. @PCF_Science PCF AR Signalling WG Webinar today, 11am ET. @AdamSharpMedOnc of @ICR_London and @Nb10Nigel of @CellCentric. pic.twitter.com/r46sZNwGXL

Stay up to date with Cellcentric and follow us on twitter

Follow us

Our team continues to expand. Looking for experienced people: Finance, Ops, Clinical Trials Manager. Enquires please to info@cellcentric.com pic.twitter.com/8KO6HYMKOH

Delighted to continue to work with @PCR_News, understanding the patient experience on clinical trials. Always learning. pic.twitter.com/xDSxHR9tRm

New paper by Nie et al. in Nature Cell Death & Disease: new therapeutic options via p300/CBP synthetic lethality. @panhammarstrom @zhangf    nature.com/articles/s4141… pic.twitter.com/2YUq2IYp5c